Quantcast

Zecevic

Alma has a Ph.D. in pathobiology from Brown University and is currently a post-doc at MD Anderson Cancer Center in Houston studying chemotherapy and DNA damage

Articles by Zecevic:

PARP-1 Inhibition: A Bench to Clinic Success Story?

Recently, someone very close to me went through chemotherapy for a fairly common yet very scary cancer. One night as we were going over her treatments and how they were going to affect the rest of her body I compared our cancer treatments to using the biggest hammer possible, hitting a building and hoping that…

19 Oct 2009 Of Interest